G71.22
Centronuclear myopathy
Clinical Classification Guidelines
Medical Intelligence & Overview
Centronuclear myopathy is a rare genetic disorder affecting the muscles, leading to weakness and muscle wasting. It is characterized by abnormal muscle cell structure, where the nuclei are located centrally within the muscle fibers, unlike normal muscle cells where the nuclei are at the periphery. This condition can vary in severity, from mild muscle weakness to significant disability, and often manifests in infancy or early childhood but can sometimes present later in life. The prognosis depends on the severity and progression of the symptoms.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting the proteins responsible for muscle fiber structure and function. Inheritance patterns are typically autosomal recessive or autosomal dominant depending on the specific gene involved. Mutations in the BIN1 or MTM1 genes, which are crucial for muscle cell stability and function, have been associated with the condition.
Key Symptoms: Muscle weakness, especially in the proximal muscles such as hips and shoulders. Muscle wasting, leading to decreased muscle mass. Delayed motor development in children, such as difficulty in walking or climbing stairs. Difficulties with swallowing or speaking in some cases. Fatigue after physical activity. Potential respiratory complications if breathing muscles are involved. In some cases, muscle stiffness or other movement disorders.
Diagnostic & Treatment
Diagnosis Path: Electromyography (EMG): Assesses the electrical activity of muscles and can reveal signs of myopathy. Muscle biopsy: Examining a small sample of muscle tissue under a microscope often reveals characteristic centronuclear features, such as centrally located nuclei within the muscle fibers. Genetic testing: Identifies mutations in genes associated with the condition, confirming the diagnosis and aiding in genetic counseling. Imaging studies: MRI may be used to assess muscle integrity and involvement. Serum creatine kinase levels: May be mildly elevated but are not definitive.
Treatment Protocols: Physical therapy: Helps maintain muscle strength, flexibility, and mobility. Occupational therapy: Assists with daily activities and adapting to muscle weakness. Respiratory support: Mechanical ventilation may be necessary if breathing muscles are affected. Assistive devices: Use of braces, wheelchairs, or other aids to enhance mobility. Nutritional support: Ensuring proper nutrition, especially if swallowing difficulties occur. Monitoring and managing complications: Regular check-ups to address respiratory or cardiac issues if they develop.
Clinical Advice & FAQs
Billing Guidance
Is G71.22 a billable ICD-10 code?
Yes, G71.22 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G71.22?
Clinical documentation must specify the nature of Centronuclear myopathy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference